New cancer drug enters first human trials

NCT ID NCT07317505

Recruiting now Disease control Sponsor: Conjupro Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated Apr 20, 2026 · Updated 17 times

Summary

This is the first study in people to test a new drug called JMT108 for advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose, see how the body processes the drug, and look for early signs that it can shrink tumors. About 270 adults will receive the drug by IV every two weeks and be monitored closely for safety and response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Carolina BioOncology Institute
RECRUITING

Huntersville, North Carolina, 28078, United States

Contact
NEXT Dallas
RECRUITING

Dallas, Texas, 75039, United States

Contact
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States

Contact

Conditions

Explore the condition pages connected to this study.

CANCER CANCER (SOLID TUMORS)